Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
about
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsPrognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisDysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancersNFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.A role for estrogen receptor phosphorylation in the resistance to tamoxifen.Immune microenvironment as a factor of breast cancer progression.PRC2 regulates RNA polymerase III transcribed non-translated RNA gene transcription through EZH2 and SUZ12 interaction with TFIIIC complex.An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patientsHigh miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.Significance of EZH2 expression in canine mammary tumors.Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.Derailed estrogen signaling and breast cancer: an authentic couple.The interaction between ER and NFκB in resistance to endocrine therapy.Oestrogen receptor negativity in breast cancer: a cause or consequence?Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis.Update of research on the role of EZH2 in cancer progression.Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms.Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
P2860
Q26782449-0E65DE15-7D08-434C-9D38-7041957E9647Q27853296-5F7D442C-DA92-45F2-8938-6256EC60410AQ34259906-EBBC8D3D-7085-4E9A-9EAA-BF8428FAFEA4Q34861658-DFDE1807-2D8F-41CB-B2B1-C993E3B4606CQ35469769-8D5D5C00-2B54-46CD-8D7E-75C58EAB9654Q35684445-6DFC6EF5-EE91-4622-81F5-F48A4B09868FQ35780464-A5A5136A-51D4-468D-9CF1-FBFDEB447687Q35885921-B3C7CEC6-4FFC-4227-8942-A57A8D05AC8EQ35927942-D059873F-F557-419A-B460-0B02123D3E6DQ36070061-8B84979F-FC78-4D27-9AE9-39A09568816DQ36098022-ECD2009A-74C9-4798-9CE4-F183BB05E97FQ36292201-9A6FF03C-AEC9-4CAC-88DE-9E9AF45E5669Q36589361-5BAD499E-2B78-4FFF-B16C-3044C495CFFCQ36924406-1D8A1CA8-E00A-44ED-AC9E-543B45A30E1AQ37529397-C0E868AE-4250-4FFF-B978-E9F5C2E7BEBCQ37911312-DA0277FC-BC04-4288-9299-91895B5B2DEDQ38019814-8516DF97-69B8-4067-A4E4-8EFFEF6F265AQ38099319-2D5644FA-9473-4B25-96C3-D887501D71C5Q38975402-BCC00511-BB55-4633-BB70-903A26691586Q39033038-F69D38E7-4001-4D5C-8389-AF73D6BBC392Q39491238-A1C45815-9536-4323-9835-A2E6CD52F358Q46799300-AC49FFEB-7330-4F97-9469-38007AFF14D5Q53237147-EE332C2B-E02A-4833-86D6-66E621E62464
P2860
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@ast
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@en
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@nl
type
label
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@ast
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@en
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@nl
prefLabel
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@ast
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@en
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@nl
P2093
P1476
Decreased expression of EZH2 i ...... fen in advanced breast cancer.
@en
P2093
A M Sieuwerts
E M J J Berns
I L van Staveren
J A Foekens
K Ruigrok-Ritstier
M E Meijer van Gelder
M P H M Jansen
S Sleijfer
P2888
P304
P356
10.1007/S10549-010-0836-9
P407
P577
2010-03-20T00:00:00Z
P5875
P6179
1019064086